**Table B13. Osteoporosis: Data Abstraction: Study Funder and Conflicts of Interest**

|   |   | **Study Characteristics** |   |   |   |   |   |   |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Journal** | **Study funder** | **Percentage of authors employed by pharmaceutical industry** | **Percentage of authors with COI from industry** | **What company makes intervention drug?** | **What company makes comparator drug?** | **Was there any assistance authoring the publication?** | **Did the publication indicate that the trial was registered?** |
| Barrett-Connor, 2006 | New England Journal of Medicine | Eli Lilly | 2/8 (25%) | 6/6 (100%) | Raloxifene: Eli Lilly | Placebo: NA | Yes | Yes |
| Black, 2007 | New England Journal of Medicine | Novartis Pharmaceuticals | 7/21 (33%) | 13/14 (93%) | Zoledronic Acid: Novartis Pharmaceuticals | Placebo: NA | No | Yes |
| Bonnick, 2006NOTE: this is a companion to Rosen 2005 | The Journal of Clinical Endocrinology & Metabolism | Merck | 3/11 (27%) | 7/8 (88%) | Alendronate: Merck and generic | Risedronate: Warner Chilcott | Yes | Yes |
| Grant, 2005 | Lancet | The UK Medical Research Council funded the central organization of RECORD | 0/14 (0%) | 3/14 (21%) | Vitamin D3: NAcalcium: NA(Shire Pharmaceutical funded the drugs, manufactured by Nycomed) | Placebo: NA | No | NR |
| Greenspan, 2006 | The Journal of Clinical Endocrinology & Metabolism | National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (K24 DK062895-03), a NCST from Procter and Gamble and the Alliance for Better Bone Health and to the General Clinical Research Center of the University of Pittsburgh by the National Institutes of Health/National Center for Research Resources (M01-RR00056) | 0/5 (0%) | 4/5 (80%) | Risedronate: Warner ChilcottArticle says it was provided by Procter and Gamble | Placebo: NACalcium and Vitamin D supplements: Provided by GlaxoSmithKlineArticle says it was provided by Procter and Gamble | NR | No |
| Jackson, 2006 | New England Journal of Medicine | Supported by the National Heart, Lung, and Blood Institute and the General Clinical Research Center program of the National Center for Research Resources, Department of Health and Human Services. The active study drug and placebo were supplied by Glaxo SmithKline Consumer Healthcare (Pittsburgh). | 0/47 (0%) | 10/47 (21%) | Calcium carbonate and vitamin D3: genericThe active study drug and placebo were supplied by GlaxoSmithKline Consumer Healthcare | Placebo: NAThe active study drug and placebo were supplied by GlaxoSmithKline Consumer Healthcare | No | Yes |
| McClung, 2006 | New England Journal of Medicine | Amgen | 4/16 (25%) | 11/12 (92%) | Denosumab: Amgen | Alendronate: generic, Merckand placebo | Yes | Yes |
| Porthouse, 2005 | British Medical Journal | Grants from Northern and Yorkshire NHS research and development, healthy ageing programme (TA, RMF, AS, IW, DJT), Shire, and Nycomed.  | 0/15 (0%) | 5/15 (33%) | Combination calcium and cholecalciferol (vitamin D3): both supplied by Shire | NA | NR | Yes |
| Prince, 2006 | Archives of Internal Medicine | Healthway Health Promotion Foundation of Western Australia and by project grant 254627 from the National Health and Medical Research Council of Australia. | 0/4 (0%) | 0/4 (0%) | Calcium carbonate tablets: multiple pharmaceutical companies and generic | Placebo tablets: NA | No | No |
| Reid, 2006 | The American Journal of Medicine | NR | 0/8 (0%) | 0/8 (0%) | Calcium citrate: genericProvided by Mission Pharmacal | Placebo: NAProvided by Mission Pharmacal  | Yes | Yes |
| Rosen, 2005NOTE: this is a companion to Bonnick 2006 but has separate NCT number  | Journal of Bone and Mineral Research | NR (clearly Merck) | 4/11 (36%) | 7/7 (100%) | Alendronate: Merck and generic | Risedronate: Warner Chilcott | No | No |
| Vogel, 2006 | Journal of the American Medical Association  | Public Health Service grants from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services; and by AstraZeneca Pharmaceuticals and Eli Lilly and Co. | 0/21 (0%) | 5/21 (24%) | Tamoxifen: Cytogen and generic | Raloxifene: Eli Lilly | Yes | Yes |